H.C. Wainwright Reiterates Buy Rating on Oncolytics Biotech (ONCY)
H.C. Wainwright analyst Pat Trucchio reiterated a Buy rating and $10.00 price target on Oncolytics Biotech (NASDAQ: ONCY).The analyst commented ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
